Drug Profile
TGF-beta type II receptor Fc-fusion protein - Acceleron Pharma
Alternative Names: TGFBRII-FcLatest Information Update: 01 Dec 2021
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Class Immunoglobulin Fc fragments
- Mechanism of Action Transforming growth factor beta1 inhibitors; Transforming growth factor beta3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary hypertension
Most Recent Events
- 22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
- 28 Dec 2020 No recent reports of development identified for preclinical development in Pulmonary-hypertension in USA